Autolus Therapeutics Plc (AUTL)
1.72
+0.03
(+1.78%)
USD |
NASDAQ |
Oct 15, 16:00
1.73
+0.01
(+0.58%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (Quarterly) : 27.95M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.95M |
| March 31, 2026 | 21.17M |
| December 31, 2025 | 35.58M |
| September 30, 2025 | 27.72M |
| June 30, 2025 | 27.77M |
| March 31, 2025 | 26.73M |
| December 31, 2024 | 30.54M |
| September 30, 2024 | 40.32M |
| June 30, 2024 | 36.61M |
| March 31, 2024 | 30.67M |
| December 31, 2023 | 25.16M |
| September 30, 2023 | 32.13M |
| June 30, 2023 | 33.35M |
| March 31, 2023 | 27.64M |
| December 31, 2022 | 26.91M |
| Date | Value |
|---|---|
| September 30, 2022 | 37.63M |
| June 30, 2022 | 38.21M |
| March 31, 2022 | 33.96M |
| December 31, 2021 | 39.64M |
| September 30, 2021 | 32.29M |
| June 30, 2021 | 32.13M |
| March 31, 2021 | 30.73M |
| December 31, 2020 | 38.73M |
| September 30, 2020 | 33.54M |
| June 30, 2020 | 31.33M |
| March 31, 2020 | 31.29M |
| December 31, 2019 | 29.37M |
| September 30, 2019 | 27.31M |
| June 30, 2019 | 26.17M |
| March 31, 2019 | 22.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | 47.76M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | -- |
| Mereo BioPharma Group Plc | 1.811M |
| Evaxion AS | 2.331M |